Abstract: Carcinoma of unknown primary origin (CUP) is one of the 10 most prevalent malignancies. CUP patients in whom a site of origin can be ascribed have better outcomes than those in which the primary tumor remains unidentified. Among the tools available to pathologists in approaching these lesions, immunohistochemistry is a reliable, inexpensive, and widely available resource. New markers continue to emerge, which, in combination with other historically useful antibodies, allow rapid and accurate identification of primary site in an increasing number of cases. This review discusses the approach to the diagnosis of CUP using immunohistochemistry and outlines some of the most useful markers with a particular focus on the utility of lineage-restricted transcription factors, including CDX2, NKX3-1, PAX8, SATB2, TTF-1, and SF1.
C arcinoma of unknown primary origin (CUP) is defined by histologically confirmed metastatic carcinoma in the absence of clinical, radiographic, or pathologic identification of a primary site. Approximately 3% to 5% of new malignant diagnoses are classified as CUP. As such, CUP ranks among the 10 most prevalent forms of cancer in both males and females. 1 The most common sites of involvement include lymph nodes, liver, bones, and lungs. 2 A review of 12 autopsy series in patients with CUP showed that a primary site was identified at autopsy in 73% of cases. The most common sites of origin included pancreaticobiliary tract, lung, and kidney. 3 Overall, patients with CUP have a poor prognosis, with median survival times of between 8 and 11 months. Clinically, approximately 15% of CUP cases can be classified into categories that predict primary site, and accordingly allow for directed therapy. Examples include female patients with axillary lymph node involvement (presumed breast primary) and squamous cell carcinoma involving cervical lymph nodes (presumed head and neck primary). These patients have improved outcomes compared with the 85% of patients in whom no primary site can be presumed and therefore no site-specific treatment can be offered. 4 As more targeted therapies emerge, the survival benefit of assigning primary site in newly diagnosed metastatic carcinomas will continue to increase. Therefore, clinicians, radiologists, and pathologists must take an active role in identifying sites of origin in metastatic carcinoma.
Immunohistochemistry has an essential role in the evaluation of biopsies and fine-needle aspirates of metastatic tumors. It has a relatively low cost compared with other techniques such as advanced imaging studies and molecular genetic analysis, and it can be performed easily on paraffin-embedded tissue, even when only scant malignant cells are present. A wide array of new immunohistochemical markers has emerged in the last decade, most notably antibodies directed against lineage-specific transcription factors, which have improved specificity for primary site determination compared with antibodies that recognize keratins and other cytoplasmic and membranous antigens. Here we review the immunohistochemical approach to biopsies of CUP with a particular focus on the application of lineage-restricted markers in this context.
KERATIN FAMILY MEMBERS IN CARCINOMA
Keratins, a family of intermediate filament proteins expressed in epithelial cells, have historically been useful in confirming epithelial origin in poorly differentiated malignancies, 5 although other tumor types, including mesothelioma 6 and some sarcomas such as synovial sarcoma 7 also express keratins. There are 54 functional keratin genes in the human genome. 8 Although the patterns are not entirely specific, differential expression of the protein products from these genes in epithelial cells from various anatomic sites can be exploited to suggest possible primary sites in the setting of metastatic CUP.
Antibodies directed against low-molecular-weight keratins, such as CK8 (including clone CAM5.2 9 ) and CK18, react with most glandular epithelial cells as well as hepatocytes. In contrast, antibodies specific for high-molecularweight keratins, such as CK5 and CK14 (including clone 34bE12, which recognizes CK1, CK5, CK10, and CK14 10 ), react predominantly with squamous epithelium and urothelium. Accordingly, antibodies directed against low-molecularweight keratins are useful to support a diagnosis of adenocarcinoma and hepatocellular carcinoma (HCC), whereas those directed against high-molecular-weight keratins are helpful to confirm the diagnosis of squamous cell carcinoma and urothelial carcinoma.
Among keratin family members, CK7 (KRT7) and CK20 (KRT20) have been most widely used to predict primary site. 11 The most common CK7 and CK20 profiles are shown in Table 1 . Although these expression patterns may be useful to prioritize one site of origin over another and to direct further workup, cases that do not fit these profiles are encountered frequently. Furthermore, the CK7-positive, CK20-negative immunophenotype is most common in CUP; this profile is not particularly helpful to suggest a specific anatomic site of origin. CK7 and CK20 therefore should not be used to invoke primary site in the absence of additional morphologic or immunohistochemical support.
LINEAGE-SPECIFIC CYTOPLASMIC AND MEMBRANOUS MARKERS
Cytoplasmic proteins associated with site-specific functions can be useful immunohistochemical markers in the workup of CUP (Table 2) . While the specificity of these markers varies, almost all of them lose sensitivity as tumors become more poorly differentiated. Therefore, their best application is in the evaluation of histologically well and moderately differentiated carcinomas. A panel of markers, with consideration for various primary sites on the clinical and radiographic differential diagnosis, provides superior support for site of origin compared with use of a single stain in isolation.
Two cytoplasmic markers used to identify breast carcinoma, mammaglobin (SCGB2A2) and gross-cystic disease fluid protein-15 (GCDFP-15; prolactin-inducible protein), are illustrative of the utility and limitations of this approach (Fig. 1) . In a large series of carcinomas from various primary sites, Sasaki et al 12 showed that mammaglobin was expressed in 48% of breast carcinomas, but not in tumors from other common sites including lung, head and neck, gastrointestinal tract, ovary, and thyroid, with the exception of 1 positive case of endometrial adenocarcinoma. Lotan et al 13 showed that mammaglobin was specific for breast primary origin in micropapillary carcinomas and demonstrated that it was useful to distinguish these tumors from bladder, lung, and ovarian primary carcinomas of this subtype, which can have extensive histologic overlap. Similarly, GCDFP-15 can identify breast origin in a number of clinically useful scenarios, including lobular carcinoma with signet-ring-cell features 14 and distinguishing breast from ovarian primary tumors. 15 Despite their utility in these situations, neither marker is commonly expressed in poorly differentiated breast carcinomas, especially basal-like carcinomas, unclassified triple-negative carcinomas, metaplastic carcinomas, and medullary carcinomas. [16] [17] [18] GCDFP-15 expression has also been reported in a small percentage of lung adenocarcinomas. 19, 20 Thus, while these markers can be useful to ascribe breast primary origin to metastatic carcinoma in the appropriate clinical setting, they are best used together as a part of a panel of stains. Negative staining should not be used as evidence against breast origin, especially in the context of a poorly differentiated carcinoma.
The traits exemplified by mammaglobin and GCDFP-15-acceptable to excellent specificity and differentiationdependent sensitivity-apply to cytoplasmic antigens in carcinomas from most other primary sites.
Napsin A is a relatively sensitive cytoplasmic marker of lung primary origin (Fig. 2) . It is expressed in 60% to 80% of lung adenocarcinomas and is only slightly less sensitive than the nuclear marker TTF-1 (NKX2-1), which is positive in 70% to 90% of these tumors. [21] [22] [23] Napsin A can be useful to include as part of a panel in the evaluation of CUP, because it is expressed in occasional tumors that are TTF-1 negative 23, 24 and, unlike TTF-1, it is rarely positive in thyroid carcinomas. 25 In contrast to TTF-1, however, napsin A is expressed in a variety of other primary carcinomas, including ovarian clear cell carcinoma, 26, 27 renal cell carcinoma (especially papillary type), 22, 25 and adrenal cortical carcinoma (ACC). 28 Furthermore, the sensitivity of napsin A decreases significantly in mucinous adenocarcinomas as well as sarcomatoid carcinoma of the lung. 29, 30 Thus, the particular histologic subtype must also be considered in the interpretation of napsin A-negative CUP. Thyroglobulin has long been utilized as an effective marker of thyroid origin in both follicular and papillary carcinomas. 31 It can be especially useful in cases for which the differential diagnosis includes primary thyroid carcinoma and metastatic renal cell carcinoma, and it has been shown to be effective in tumors from other sites that morphologically resemble papillary thyroid carcinoma. 32 Its sensitivity decreases dramatically from 90% to 100% reactivity in well-differentiated carcinomas to <20% in poorly differentiated or anaplastic thyroid carcinomas. 31, 33 Although it is relatively specific, occasional cases of papillary carcinomas arising from the ovary that express thyroglobulin have been described. 34 Renal cell carcinoma marker (RCC), also known as GP200 (podocalyxin-like), is the most widely utilized cytoplasmic marker of tumors of renal origin in the metastatic setting. 35 McGregor and colleagues demonstrated outstanding sensitivity of RCC marker for the 2 most common types of renal cell carcinoma, clear cell and papillary types, which were positive in 84% and 95% of cases, respectively. In contrast, chromophobe renal cell carcinoma showed variable staining, with only 45% of cases positive, and only 22% of sarcomatoid carcinomas were reactive. No collecting duct carcinomas were positive. Specificity was high in this study, with significant reactivity in nonrenal tumors seen only in parathyroid adenomas and a subset of breast and testicular tumors. 36 However, Bakshi et al 37 subsequently demonstrated much lower specificity with over 20% of adrenal cortical, colorectal, breast, prostatic, and cervical carcinomas showing reactivity as well as 17% of malignant melanomas. shows diffuse cytoplasmic staining for GCDFP-15 with variable intensity (B) and diffuse strong GATA3 nuclear expression (C). In contrast, a more poorly differentiated invasive ductal carcinoma (D) shows only limited cytoplasmic staining for mammaglobin (E), but GATA3 nuclear expression remains diffuse and strong (F) (A and D: hematoxylin and eosin, Â400; B, C, E, and F: immunoperoxidase, Â 400).
Therefore, although RCC marker has some utility in defined clinical scenarios, such as distinguishing metastatic renal cell carcinoma to the brain from central nervous system hemangioblastoma in von Hippel-Lindau syndrome, 38 its reactivity in other tumor types and its decreased sensitivity in a subset of renal cell carcinomas warrant caution in using this marker in the context of CUP. Of note, the sensitivity of RCC marker in metastatic clear cell and papillary renal cell carcinomas is lower than in primary tumors (67% and 83%, respectively) with most metastatic cases showing a more limited staining distribution. 36 Pan et al, 39 in a study of matched primary and metastatic renal cell carcinomas, suggested that loss of expression in the metastatic setting may be even more frequent when they demonstrated that up to 50% of primary renal tumors that were positive for RCC marker lost expression at sites of metastasis.
Identification of HCC is critical, both in the metastatic setting as well as in distinguishing primary HCC from metastatic carcinomas to the liver. Although well-differentiated HCC can be readily diagnosed based on classic morphologic features, immunohistochemistry is often required in more poorly differentiated tumors. There is no lineage-restricted nuclear transcription factor to specifically mark hepatocellular origin that has been reproducibly characterized to date. Accordingly, cytoplasmic protein targets are often used in this scenario. A panel of markers, including HepPar-1, glypican-3, and arginase-1, has been shown to be most useful in this context. 40 HepPar-1 (Figs. 3A, B) , an antibody that recognizes the carbamoylphosphate synthetase 1 protein, was originally shown to have 80% to 90% sensitivity and specificity for hepatocellular origin, 41 but more recently, it has been demonstrated to be negative in >50% of poorly differentiated HCC, the scenario in which immunohistochemistry is most likely to be required. 42 Furthermore, occasional cases of esophageal, gastric, and lung adenocarcinomas may express HepPar-1 (in our experience, particularly common in the stomach). 42 Glypican-3 is useful to distinguish HCC from benign hepatocellular proliferations, although this marker shows low sensitivity in well-differentiated HCC. Furthermore, its expression in a number of other tumor types, including squamous cell carcinoma of the lung and germ cell tumors, limits its utility in the setting of CUP. 43, 44 Arginase-1 holds more promise as a useful marker of hepatocellular origin in poorly differentiated carcinomas (Figs. 3C, D ). Yan and colleagues demonstrated diffuse strong reactivity in 82.1% of HCCs, including 53.6% of poorly differentiated tumors. In contrast, only 14.3% of poorly differentiated HCC showed diffuse strong HepPar-1 reactivity. Furthermore, in a comprehensive panel of tumors from other sites, only 1 case of intrahepatic cholangiocarcinoma and 1 case of prostatic adenocarcinoma were arginase-1 positive. 45 Subsequent studies have demonstrated that arginase-1 is more sensitive and specific than other commonly used markers in diagnosing HCC in small biopsy and fine-needle aspiration specimens. 46 Arginase-1 therefore is the best available marker for hepatocellular origin in poorly differentiated carcinomas, although a panel of cytoplasmic markers is advisable given the relatively low sensitivity of each individual marker in poorly differentiated tumors.
Metastatic prostatic adenocarcinoma is commonly encountered in the differential diagnosis of CUP in male patients. Two cytoplasmic markers, prostate-specific antigen (PSA, Fig. 4 ) (kallikrein-related peptidase 3) and prostatespecific acid phosphatase (PAP) are useful to ascribe prostatic origin in the metastatic setting, as well as to distinguish locally advanced prostatic adenocarcinoma from urothelial carcinoma. [47] [48] [49] The sensitivities of both markers are >90% for all prostatic adenocarcinomas, including many poorly differentiated tumors, 50 but are lower in some variants, such as small cell carcinomas of prostatic origin. 51 Some strategies that have been proposed to increase the sensitivity of PSA immunohistochemistry include using polyclonal over monoclonal antibodies 52 and targeting precursor forms of PSA (proPSA), 53 but in practice most tumors of prostatic origin are positive regardless of the antibody utilized. However, the extent of staining is often limited in metastases; only a small subset of tumor cells typically show cytoplasmic reactivity in such cases. Both markers are highly specific although rare instances of reactivity in other tumor types, most commonly breast carcinoma and salivary gland neoplasms, have been documented. [54] [55] [56] [57] [58] [59] Villin, the most commonly used membranous marker of metastatic colorectal adenocarcinomas, was originally shown to be expressed in the brush border of epithelial cells from the intestine, liver, pancreas, and proximal renal tubules. 60 Subsequently, expression was demonstrated in primary and metastatic colorectal adenocarcinomas, but also in a subset of gastric, renal cell, endometrial, ovarian, and lung carcinomas. 61, 62 Although these early studies showed relatively high sensitivity, villin expression can be lost in more poorly differentiated tumors such as medullary colon carcinomas, which are better identified using nuclear transcription factor markers. 63 The expression of villin in carcinomas from other sites as well as its loss in poorly differentiated colorectal carcinomas has led to declining use in clinical practice, although some authors recommend it as part of a panel with nuclear markers in defined clinical scenarios, such as the distinction between metastatic colorectal carcinoma and primary adenocarcinomas of the bladder. 64 As the adrenal gland is a common site of metastasis, exclusion of primary ACC is critical in the evaluation of CUP. Inhibin, melan A/MART1, and calretinin are among the most widely used cytoplasmic markers of adrenal cortical origin; all have been shown to have sensitivities approaching or exceeding 90%. 65, 66 Although highly sensitive, expression of these markers is commonly observed in a limited number of other tumor types, including other steroid-producing tumors such as sex-cord stromal tumors (all 3 markers) 67 and melanocytic neoplasms (melan A/ MART1). 68 Although none of these markers are entirely specific for ACC, they can be extremely useful in certain commonly encountered clinical scenarios. Sangoi et al 69 found that each of these markers was positive in 85% to 90% of primary adrenal cortical lesions but in r10% of metastatic renal cell carcinomas. Renshaw and Granter 70 demonstrated that inhibin and melan A clone A103 were sensitive and specific markers to distinguish ACC from HCC. Importantly, unlike A103, the other widely available MART1/melan A clone, M2-7C10, does not stain adrenal cortical lesions at a significant rate. 68 Uroplakin 3 has historically been used in the identification of urothelial carcinoma. Although relatively specific, its clinical utility is limited by low sensitivity, particularly in the metastatic setting. 71, 72 Recently, new antibodies directed against another uroplakin family member, uroplakin 2, have demonstrated improved, albeit still relatively low sensitivities on the order of 50% to 80%, compared with levels of 15% to 50% for uroplakin 3. [73] [74] [75] Neither marker is commonly expressed in carcinomas from other sites. Thus, while positive uroplakin staining can be helpful to ascribe urothelial origin, absence of staining is not a reliable finding to exclude urothelial carcinoma from the differential diagnosis.
LINEAGE-RESTRICTED TRANSCRIPTION FACTORS
In the last decade, transcription factors with lineagespecific expression have been described for carcinomas arising from many organ systems. In general, these markers offer superior sensitivity-especially in poorly differentiated tumors-and specificity compared with the cytoplasmic markers described above. Unlike the cytoplasmic proteins, which are generally involved in cell-specific functions, most of these proteins are transcription factors essential for organ-specific development and lineage commitment. Accordingly, their expression patterns are often preserved, even in the context of poorly differentiated carcinoma. Some of the most widely used and extensively characterized of these nuclear markers are described below.
CDX2
CDX2, a transcription factor involved in intestinal differentiation, was one of the first nuclear markers widely used to ascribe site of origin in CUP. In large cohorts of carcinomas from various primary sites, Werling et al 76 and Moskaluk et al 77 demonstrated exceptional sensitivity of CDX2 for colorectal primary tumors, with diffuse positivity seen in >90% of cases in both studies. Werling and colleagues demonstrated superior sensitivity compared with villin and also showed no significant loss of reactivity in the metastatic setting compared with primary tumors. Subsequent studies demonstrated some loss of sensitivity in histologically high-grade tumors, although even in this category >50% of tumors were positive. 78, 79 In addition to colorectal tumors, carcinomas from other gastrointestinal primary sites that are commonly associated with intestinal differentiation, such as gastroesophageal and pancreaticobiliary adenocarcinomas, are frequently positive, although several of the early survey studies noted a more heterogenous distribution of staining (as opposed to strong and diffuse staining typical of colorectal adenocarcinomas) in these cases. [76] [77] [78] Expression in tumors from these sites may also be dependent on degree of differentiation. Although commonly expressed in gastric (intestinal-type) dysplasia and early carcinomas, CDX2 expression may be seen in <30% of advanced gastric carcinoma. 80 Overall, however, its high degree of sensitivity, especially for colorectal adenocarcinomas, has made CDX2 one of the most commonly used nuclear stains in the workup of CUP.
Although its specificity is generally quite high (Table 3) , CDX2 can be expressed in some nongastrointestinal tumors, especially those with intestinal or intestinal-like phenotypes. In their early survey, Werling et al 76 described CDX2 reactivity in 2 of 2 bladder adenocarcinomas (but not in any of 21 urothelial carcinomas). However, in a subsequent series of 17 bladder adenocarcinomas, <50% of tumors were CDX2 positive, with only 24% of cases showing diffuse reactivity. 64 Although most lung adenocarcinomas are CDX2 negative, invasive mucinous adenocarcinomas are commonly positive, especially those with goblet cell-like cytomorphology. 81 Some studies have demonstrated that, unlike invasive mucinous lung tumors, mucinous adenocarcinoma in situ (formerly mucinous bronchioloalveolar carcinoma) is infrequently CDX2 positive. 82 One clinical scenario in which CDX2 can be particularly useful is in the setting of a female patient with a poorly differentiated or signet-ring cell type gastric adenocarcinoma (Fig. 5) , which must be distinguished from a metastatic lobular or mixed-type breast carcinoma to the stomach. Given its rare positivity in breast carcinomas, CDX2 can be a useful marker to establish gastric primary origin, especially in combination with estrogen receptor (ER) and progesterone receptor (PR) negativity. 83 Distinguishing metastatic colorectal adenocarcinoma from mucinous adenocarcinoma of the ovary is a common diagnostic dilemma in clinical practice. Although absence of CDX2 staining can be helpful to favor the latter, numerous studies have demonstrated that CDX2 is expressed in a subset of ovarian mucinous and endometrioid adenocarcinomas. In a series of 23 primary ovarian tumors, Logani and colleagues found CDX2 expression in approximately 50% of cases. Although the majority of positive cases showed heterogenous staining, 5 cases (22%), including 3 mucinous and 2 endometrioid tumors, showed diffuse staining. 84 Vang et al 85 found similar results: CDX2 expression was observed in 36% of cases, including 18% with diffuse reactivity. Other studies have also identified CDX2 positivity in cervical adenocarcinomas, especially the endometrioid subtype. 86 Interestingly, however, De Lott et al 79 found CDX2 expression in only 5.9% of 256 endometrial carcinomas. Thus, reactivity for CDX2 alone is insufficient to establish a diagnosis of metastatic colorectal, appendiceal, or gastric carcinoma to the ovary if the morphologic and clinical differential diagnosis also includes a mucinous or endometrioid ovarian or cervical primary carcinoma. However, CDX2 does have utility in the distinction between metastatic colorectal and endometrial carcinomas.
SATB2
Although its high level of sensitivity makes CDX2 a useful marker in the workup of CUP, its specificity is limited in some of the common clinical scenarios described above. SATB2 is a more recently described marker of colorectal origin with a similarly high level of sensitivity and increased specificity compared with CDX2 (Fig. 6) . Its expression in normal epithelial cells is limited to the appendix, colon, and rectum, and it is positive in 80% to 90% of primary and metastatic colorectal carcinomas. 87, 88 SATB2 is also expressed in medullary carcinomas of the colon more frequently than CDX2. 63 Lower levels of expression have been described in poorly differentiated tumors, but at least focal reactivity is usually present even in these cases. 89 Magnusson et al 87 and Dragomir et al 88 have shown that SATB2 is particularly useful when combined with CK20 to identify tumors of colorectal origin (Table 4) . Renal cell carcinomas are the only other carcinomas with moderate to strong expression (25% to 35% of cases). Mullerian primary carcinomas are positive in <20% of cases (predominantly in a weak/focal pattern), although detailed studies of SATB2 reactivity in subtypes of Mullerian carcinomas have not yet been performed. Unlike CDX2, SATB2 is rarely expressed in gastroesophageal, small intestinal, or pancreaticobiliary carcinomas. Lung carcinomas are also rarely positive, although specific data on mucinous lung tumors are not available. SATB2 transcriptional activation is also necessary for osteoblast development, and it is expressed in most osteosarcomas, 90 although these tumors are unlikely to be confused with colorectal carcinomas.
GATA3
GATA3, a transcription factor originally recognized for its role in T-cell development and function, has recently been shown to be clinically useful as a marker of breast or urothelial origin in metastatic carcinomas. 91 In early survey studies, expression was found to be limited to breast (Fig. 1) and urothelial (Fig. 7) carcinomas. 92 In a subsequent analysis of over 1100 tumors, Liu and colleagues found GATA3 reactivity in 86% of urothelial carcinomas, 91% of ductal breast carcinomas, and 100% of lobular breast carcinomas. Among other tumor types, only 2 cases (2%) of endometrial carcinoma were GATA3 positive. 93 More recent studies have confirmed the high degree of sensitivity of GATA3 for these organs, but the specificity has been more variable (Table 5 ). In an analysis of 2500 tumors, the largest survey of GATA3 expression to date, Miettinen and colleagues found reactivity in over 80% of breast and urothelial carcinomas, but also in a subset of basal cell carcinomas, squamous cell carcinomas, skin adnexal tumors, choriocarcinoma, endodermal sinus tumors, and paragangliomas. Furthermore, expression was seen in 58% of malignant mesotheliomas, 51% of chromophobe renal cell carcinomas, 43% of salivary duct carcinomas, and 37% of pancreatic adenocarcinomas. 94 It is also expressed in squamous cell carcinomas of the vulva and cervix and in parathyroid lesions. 95, 96 Among salivary gland tumors, mammary analogue secretory carcinomas express GATA3 in most cases. 97 Although now considered less specific for breast and urothelial carcinoma than originally proposed, its high level of sensitivity still makes GATA3 a useful marker in the workup of CUP. In a direct comparison, GATA3 was shown to be more sensitive for urothelial carcinoma than either of the cell membrane markers thrombomodulin or uroplakin 3. 98 Importantly, its expression is preserved in urothelial carcinomas in the metastatic setting as well as in histologic types that may be more difficult to identify on morphologic grounds, such as the micropapillary variant. 99 ,100 GATA3 has been recommended as part of a panel of stains (also including CK20, p63, and either highmolecular-weight keratin or CK5/6) by the International Society of Urologic Pathology to establish the diagnosis of urothelial primary carcinoma, although it was noted by this group that "no ideal marker" is available for this purpose. 101 GATA3 is generally not a reliable marker for adenocarcinoma of the bladder, although it is expressed in a subset of signet-ring-cell carcinomas at this site. 102 The utility of GATA3 in the setting of breast carcinoma also stems from its high sensitivity. It is expressed in the majority of poorly differentiated breast carcinomas, which are often negative for GCDFP-15 and mammaglobin, including mucinous, medullary, and micropapillary variants, and it is positive in most ER-negative breast carcinomas. 103, 104 In a direct comparison with GCDFP-15, GATA3 was shown to be more sensitive and specific for discriminating between breast carcinoma and primary lung carcinomas when used in a panel with TTF-1 and napsin A. 19 Thus, GATA3 remains a highly useful marker of breast and urothelial primary origin, although knowledge of its expression in carcinomas from other sites is critical to prevent misinterpretation in specific clinical contexts.
NKX3-1
NKX3-1 is a homeobox transcription factor whose expression has long been known to be androgen dependent and restricted to the prostate. 105 Although PSA and PAP are generally quite useful markers for ascribing prostatic origin in CUP as reviewed above, NKX3-1 is an attractive nuclear marker, which may be useful in the occasional cases lacking cytoplasmic reactivity for these proteins or in situations in which the interpretation of faint cytoplasmic reactivity may be ambiguous (Fig. 4) .
NKX3-1 is a tumor suppressor gene shown to be downregulated in advanced neoplasia; early attempts to characterize NKX3-1 expression by immunohistochemistry were complicated by an absence of staining in clinically higher stage cases, including poorly differentiated tumors and metastases. 106 In 2007, however, Chuang and colleagues demonstrated the utility of a novel polyclonal antibody directed against a recombinant polypeptide representing the N-terminal 123 amino acids of NKX3-1. They showed that this antibody was a useful marker to distinguish high-grade prostatic adenocarcinoma from urothelial carcinoma. 50 Subsequently, Gurel et al 107 performed a large survey study including 69 metastatic prostatic adenocarcinomas and 349 tumors from other sites. They found NKX3-1 reactivity in 68 (98.6%) metastatic prostatic carcinomas and in only 1 case of a tumor not derived from the prostate (a lobular breast carcinoma).
Subsequent analysis has confirmed that NKX3-1 can be expressed weakly in a minority of breast cancer cases, especially androgen receptor and ER-positive lobular carcinomas. 108 Nevertheless, and especially given the low prevalence of male breast cancer, NKX3-1 remains a useful ancillary test in the setting of advanced prostatic adenocarcinoma (Table 6 ), as illustrated in recent work describing its role in tumors with pseudopapillary features, which may mimic urothelial carcinomas. 109 Of note, similar to other markers of prostatic origin, its sensitivity is poor (< 20%) in the setting of small cell carcinoma. 110 
PAX8
In the last decade, PAX8 has become one of the most widely used lineage-specific transcription factors in the immunohistochemical approach to CUP. Multiple studies from 2008 and 2009 independently demonstrated an exceptionally high level of sensitivity for carcinomas originating from the ovary, kidney, and thyroid. Nonaka et al 111 showed that over 90% of serous, endometrioid, and clear cell ovarian carcinomas were positive for PAX8, a superior level of sensitivity compared with the widely used and potential downstream target of PAX8, WT1. 112 One notable exception to the high frequency of reactivity in the study by Nonaka and colleagues was ovarian mucinous carcinomas, which were positive in only 8.3% of cases. The same group also showed in a separate study that most thyroid carcinomas, including 100% of papillary, follicular, and poorly differentiated carcinomas, 79% of anaplastic carcinomas, and 75% of medullary carcinomas were PAX8 positive (Fig. 8) . 113 The following year, Tong and colleagues demonstrated PAX8 expression in a variety of renal cell carcinomas, with reactivity in over 90% of clear cell and papillary types, over 80% of chromophobe renal cell carcinomas, and in the sarcomatoid component of approximately 70% of tumors with such features. Importantly, high levels of staining were retained in the metastatic setting. 114 Subsequent studies also described PAX8 expression in >90% of thymomas, 77% of thymic carcinomas, and a subset of epithelial tumors from the male genital tract. 115, 116 Because of its higher sensitivity, PAX8 has largely supplanted the use of another PAX family member, PAX2, which is positive in most gynecologic and renal carcinomas, but is not typically expressed in thyroid or thymic tumors. 117 The specificity of PAX8 in the setting of CUP was demonstrated in 3 comprehensive survey studies published in 2011 (Table 7) . Laury and colleagues found high levels of expression in tumors arising throughout the Mullerian tract, including endometrial adenocarcinomas and cervical carcinomas (both adenocarcinoma and squamous cell carcinoma), in addition to ovarian, renal, thyroid, and thymic tumors. Other tumors with PAX8 reactivity included clear cell adenocarcinoma of the bladder (100% of cases), urothelial carcinoma (18%), cholangiocarcinoma (100% of only 2 total cases), esophageal adenocarcinoma (25%), pancreatic adenocarcinoma (8%), acinic cell carcinoma of the salivary gland (33%), squamous cell carcinoma of the lung (33%), and mixed germ cell tumors of the testis (43%). 118 Ozcan et al 119 demonstrated a similar staining distribution and also described PAX8 reactivity in 42% of parathyroid adenomas and 100% of lymphomas as well as in benign lymphoid tissue, a pattern to note in order to avoid false-positive results in malignancies with abundant FIGURE 7. GATA3 in urothelial carcinoma. A high-grade urothelial carcinoma (A: hematoxylin and eosin, Â400) shows diffuse, strong nuclear GATA3 expression (B: immunoperoxidase, Â400). tumor-associated lymphocytes. Woodard et al 120 described a similar pattern, although no pancreatic ductal adenocarcinomas or cholangiocarcinomas were positive in larger cohorts of these lesions compared with those evaluated by Laury et al. 118 Of note, each of these studies used a polyclonal PAX8 antibody; the expression in thymic tumors likely represents cross-reactivity with other Pax family members. Toriyama et al 121 have recently demonstrated that a monoclonal PAX8 antibody is negative in thymic tumors and provides superior specificity in the context of metastatic thyroid carcinoma to the lung. Cross-reactivity with PAX5 is also responsible for immunoreactivity in most lymphomas using polyclonal anti-PAX8 antibodies. 122 The utility of PAX8 has been demonstrated in a number of specific challenging diagnostic scenarios. One example is the distinction between metastatic clear cell renal cell carcinoma and central nervous system hemangioblastomas, both of which have been associated with von Hippel-Lindau syndrome and can have significant morphologic overlap. 123 Other studies have shown that PAX8 is rarely expressed in malignant mesothelioma, making it useful to distinguish this tumor type from ovarian serous carcinoma and renal cell carcinoma. [124] [125] [126] Finally, although a comprehensive algorithmic approach to assigning primary site to neuroendocrine tumors has been reviewed elsewhere, 127 it is worth noting that the polyclonal anti-PAX8 antibody is a reliable marker of pancreatic origin in this context (again representing cross-reactivity, in this case with PAX6). [128] [129] [130] TTF-1 (NXK2-1)
Thyroid transcription factor 1 (TTF-1), like CDX2, is a lineage-specific transcription factor that has a long history of application in clinical practice. Originally named for its role in activating transcription from the thyroglobulin promoter, 131 TTF-1 can be detected by immunohistochemistry in the nucleus of normal and neoplastic thyroid follicular cells. 132 Its most widely used application, however, is to ascribe lung origin to metastatic and primary adenocarcinomas, an especially useful role given that the lung is often a site of metastasis and conversely that lung adenocarcinomas are commonly encountered in other sites presenting as CUP (Fig. 8) .
In 1996, Bejarano et al 133 described TTF-1 expression in 76% of lung adenocarcinomas, 1 of 8 gastric carcinomas, 1 of 8 endometrial carcinomas, and in no cases of carcinoma from the breast, colon, or prostate, nor in any cases of epithelioid mesothelioma. TTF-1 was soon shown to be expressed primarily in pulmonary adenocarcinomas without preference for a specific histologic pattern and only very rarely in squamous cell carcinomas. 134 Subsequent studies have generally shown similar levels of sensitivity but also slightly lower specificity in certain settings (Table 8) . 25, [135] [136] [137] [138] [139] [140] In a large survey series of primary carcinomas, Bishop et al 21 found no staining in any colorectal, pancreatic, breast, or renal carcinomas. Mukhopadhyay and colleagues reported similar results with 82% of pulmonary adenocarcinomas and 90% of thyroid carcinomas staining, but no expression in any breast, colon, kidney, pancreatic, urothelial, prostatic, esophageal, hepatocellular, gastric, endometrial, ovarian, or ampullary carcinomas. However, some larger series of tumors from other sites have shown lower levels of specificity for lung and thyroid primary origin. Robens et al 141 identified TTF-1 staining in 2.4% of breast carcinomas, most of which showed a focal and weak pattern of staining. Surrey et al 142 found TTF-1 staining in 27.2% of cholangiocarcinomas, all of which were extrahepatic. Siami et al 143 reported TTF-1 expression in 4% of endocervical adenocarcinomas and 19% of endometrial adenocarcinomas, although reactivity was focal in the majority of positive cases. The same group subsequently reported TTF-1 nuclear staining in 7 of 19 whole-tissue sections of serous ovarian carcinomas, as well as in 1 of 5 endometrioid adenocarcinomas and 1 of 3 clear cell carcinomas. However, no cases were positive in 138 tissue microarray cores of serous carcinoma, again suggesting that only focal positivity is present in most of these tumor types. 144 Other tumors in which TTF-1 staining has been reported include nephroblastoma (16.6%), 145 extrapulmonary adenoid cystic carcinoma (41.7%), 146 and ependymoma (7.4%). 147 Some data suggest that the sensitivity and specificity of TTF-1 in ascribing site of origin is dependent on the antibody clone used. 148, 149 TTF-1 expression can be useful in poorly differentiated tumors when positive, but negative staining does not reliably exclude a lung primary. Although some studies have shown reactivity in >80% of histologically poorly differentiated lung adenocarcinomas, 138 Rossi et al, 150 in a cohort of 75 adenocarcinomas with pleomorphic or sarcomatoid features, showed that just over 50% of these tumors were TTF-1 positive. Terra et al 30 reported similar findings, with TTF-1 staining in 61% of pulmonary sarcomatoid carcinomas. In addition, 40% to 80% of mucinous lung adenocarcinomas express TTF-1, which, when present, can be useful to distinguish these lesions from metastatic colorectal carcinomas as mucinous tumors from both sites can express CDX2. 81, 151 One potential diagnostic pitfall in the interpretation of TTF-1 immunohistochemistry is the relatively common occurrence of cytoplasmic staining, which is found in a number of different tumor types and is generally considered nonspecific. 152 Cytoplasmic TTF-1 staining is most commonly seen in benign and neoplastic hepatocytes, which likely represents cross-reactivity with carbamoyl phosphate synthetase 1 (ie, the antigen recognized by the HepPar-1 antibody). [153] [154] [155] [156] [157] A subset of adenocarcinomas from various anatomic sites also shows cytoplasmic staining for TTF-1. Although some have pointed out the potential diagnostic utility of TTF-1 in distinguishing HCC from histologic mimics, caution is warranted in making this interpretation without other immunohistochemical support for hepatocellular origin, given the relatively low specificity of this pattern.
Finally, TTF-1 is expressed in most well-differentiated neuroendocrine tumors (carcinoid tumors) of the lung; it is a useful marker to ascribe pulmonary origin to these 
SF1
In addition to the lineage-specific transcription factors described above, new markers continue to emerge which will undoubtedly further improve the ability of pathologists to assign site of origin in CUP. One example of a relatively recently described immunohistochemical marker is steroidogenic factor 1 (SF1) (NR5A1). Zhao and colleagues in 2009 showed that SF1 is the most sensitive marker of sexcord stromal tumors in a comprehensive panel that included many of the traditionally used markers such as Wilms tumor 1 (WT1), MART1, inhibin, calretinin, and CD99. 67 More recently, SF1 has been shown to be a highly sensitive marker of adrenal cortical neoplasms (Fig. 9) . [161] [162] [163] Sangoi and colleagues showed that SF1 was particularly useful in distinguishing primary ACC from metastatic renal cell carcinomas, with 86% of the former and no cases of the latter expressing SF1. Although additional studies-and specifically comprehensive surveys including tumors from diverse primary sites-are needed to precisely define its diagnostic utility, SF1 has the potential to be a valuable stain to exclude primary adrenal neoplasms in this very common site of metastasis.
OTHER NUCLEAR MARKERS Estrogen Receptor and Progesterone Receptor
In addition to their role as predictive biomarkers in breast carcinomas, ER and PR can be useful in ascribing primary origin to CUP in certain contexts. Although ER and PR are clearly not positive in all cases of breast carcinoma, hormone receptor-positive primary tumors retain expression in metastatic foci in over 90% of cases. 164 Therefore, these markers are most useful in patients with a known history of hormone receptor-positive breast carcinoma who may have other known or suspected primary malignancies. In addition to breast carcinomas, ER and PR are also commonly expressed in gynecologic primary carcinomas; approximately 75% of ovarian serous carcinomas express ER, which in the setting of a primary ovarian mass can be useful to distinguish serous from clear cell tumors. The latter are positive in only 10% of cases. 165 Several commonly encountered clinical scenarios in which ER staining in particular may be useful for the workup of CUP have been described. Nash et al, 166 in a study of 92 primary and metastatic liver tumors, showed that ER was expressed in 35% of metastatic breast carcinomas but not in any cases of hepatocellular, biliary, pancreatic, gastric/esophageal, or colorectal carcinomas. PR was positive in 29% of metastatic breast carcinomas, but was significantly less specific, with expression in 31% of cholangiocarcinomas and occasional gastric/esophageal, hepatocellular, and pancreatic carcinomas. Lee et al 167 demonstrated that ER and PR expression could distinguish between breast and lung, but not ovarian, metastases in pleural fluid specimens. ER and PR are also commonly expressed in metastatic breast carcinomas to the stomach, but ER in particular is almost never positive in primary gastric adenocarcinomas. 83 Because mucinous tumors can exhibit altered expression of many immunohistochemical markers as described above, they can be particularly difficult when encountered as CUP. Chu et al 168 examined ER expression in mucinous adenocarcinomas from various primary sites and found that it was positive in 88% of mucinous breast carcinomas as well as in occasional cases of cervical, endometrial, and ovarian adenocarcinomas, but was negative in all mucinous tumors arising in the bladder, gastrointestinal tract, and lung. Although it is sensitive for the detection of mucinous breast carcinoma, ER is not useful in the more common diagnostic dilemma of distinguishing primary mucinous tumors of the ovary from metastases. Vang et al, 169 in an analysis of 52 primary ovarian tumors, showed that ER and PR were expressed in most cases of primary ovarian mucinous borderline tumors, but not in invasive mucinous carcinomas of the ovary, thus limiting its diagnostic utility in this context.
WT1
WT1 is a transcription factor that plays a multitude of roles in cancer biology depending on tumor type and biological context. 170 Consistent with its functional complexity, WT1 is expressed in a variety of seemingly unrelated tumor types, including malignant mesothelioma, desmoplastic small round cell tumor, and primary ovarian serous carcinoma. [171] [172] [173] Several groups have shown that WT1 is positive in over 90% of serous ovarian carcinomas, but rarely in serous carcinomas arising in the endometrium, which makes it a particularly useful marker for identifying site of origin in CUP from female patients with high-grade serous morphology. [174] [175] [176] This difference in staining pattern was present in a meta-analysis of endometrial and ovarian serous carcinoma studies, 177 although some groups have more recently shown WT1 expression in all serous carcinomas arising from the Mullerian tract regardless of site or origin. 178 These differences may be due to reaction conditions or different interpretation of weak staining. Nonetheless, diffuse strong WT1 expression favors ovarian origin in this scenario.
Among carcinomas, WT1 is relatively specific for ovarian serous tumors, although occasional primary carcinomas from other sites are also positive. Cytoplasmic WT1 staining is detected in a subset of other carcinomas and other neoplasms 179 ; only nuclear staining should be considered positive for reliably assigning site of origin. In a comprehensive analysis of 494 malignancies, Nakatsuka and colleagues found nuclear WT1 expression in rare (5% to 15%) gastric, lung, urothelial, and breast carcinomas. The monoclonal antibody 6F-H2 was more sensitive for ovarian serous carcinomas than the polyclonal antibody C- 19. 179 p63 and p40
The p53 family member p63 and its isoform DNp63 (recognized by an antibody designated p40) are expressed in most normal stratified epithelia and their associated neoplasms, including squamous cell carcinomas from the head and neck, lung, skin, cervix, and anus as well as urothelial carcinomas and thymic tumors. 180, 181 A comprehensive immunohistochemical analysis of p63 in normal and neoplastic tissues by Di Como et al 181 found that it is rarely expressed in glandular epithelium. Other groups have shown that p63 expression is present in adnexal tumors of the skin, but metastatic adenocarcinomas to this site are rarely positive. 182, 183 Although p63 and p40 are not specific for a single primary site, they are often used in the workup of a poorly differentiated CUP to evaluate for squamous differentiation. There are currently no immunohistochemical markers that are specific for a single anatomic location in the evaluation of metastatic squamous cell carcinoma, but knowing that a tumor shows squamous differentiation can narrow the clinical and radiographic differential diagnosis. Furthermore, this distinction has important treatment implications, perhaps best exemplified by non-small cell lung carcinomas. Along with TTF-1, p63 is considered an appropriate first-line test for the classification of these tumors in FNA and small biopsy specimens. 184, 185 However, p63 is also expressed in a subset of adenocarcinomas at this site; Sholl et al 186 reported at least focal staining for p63 in 29% of lung adenocarcinoma. Similarly, Bishop et al 187 showed that both p63 and p40 are extremely sensitive in differentiating pulmonary squamous cell carcinoma from adenocarcinoma, but that p40 shows significantly higher specificity (66% and 100%, respectively).
CONCLUSIONS
Immunohistochemistry is an efficient and cost-effective approach to identifying site of origin in CUP. It is accessible to most anatomic pathologists and can be performed on relatively limited amounts of formalin-fixed paraffinembedded tumor tissue. The lineage-specific transcription factors described above have proven to be particularly sensitive and specific markers, even in many cases of histologically poorly differentiated carcinomas. Many other emerging markers hold exciting promise as new immunohistochemical targets. As the menu of available markers expands and as we further define the spectrum of reactive tumor types for each one, the proportion of CUP cases in which pathologists can confidently assign primary site will continue to increase.
